Eli Lilly and Novo Nordisk are currently the only drugmakers with FDA approved weight-loss medicines on the U.S. market.

Novo Nordisk faces challenges in the competitive GLP-1 market, but its strong brand and R&D create opportunities for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong with when investing in for the long term. They are leade ...

That makes Novo Nordisk stock the least risky way to play this trend. Should you invest $1,000 in Novo Nordisk right now? ... Don’t miss out on the latest top 10 list, ...

Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, ... Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

Novo Nordisk is ending its relationship with the company, removing its ability to sell the uber-popular drug Wegovy. Novo alleges Hims & Hers was not following standards and was endangering patient ...

Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid ...